NASDAQ:PULMPulmatrix Stock Price, Forecast & News

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PULM shares have increased by 21.7% and is now trading at $1.68. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pulmatrix.

Pulmatrix is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Pulmatrix.

Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings results on Thursday, May, 14th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. The biotechnology company had revenue of $2.76 million for the quarter. Pulmatrix had a negative return on equity of 107.55% and a negative net margin of 188.59%. View Pulmatrix's earnings history.

Shares of Pulmatrix reverse split before market open on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

1 brokers have issued 1-year target prices for Pulmatrix's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Pulmatrix's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 495.2% from the stock's current price. View analysts' price targets for Pulmatrix.

Media stories about PULM stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pulmatrix earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutPulmatrix.

Pulmatrix saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,320,000 shares, a decline of 19.0% from the April 30th total of 1,630,000 shares. Based on an average trading volume of 992,500 shares, the short-interest ratio is currently 1.3 days. Currently, 7.1% of the company's shares are short sold. View Pulmatrix's Current Options Chain.

Some companies that are related to Pulmatrix include Aptinyx (APTX), Tiziana Life Sciences (TLSA), Chembio Diagnostics (CEMI), Kindred Biosciences (KIN), Aquestive Therapeutics (AQST), Mustang Bio (MBIO), Newron Pharmaceuticals (NWPHF), CELYAD SA/ADR (CYAD), Sol Gel Technologies (SLGL), Evolus (EOLS), Immunic (IMUX), Arbutus Biopharma (ABUS), Rockwell Medical (RMTI), Aldeyra Therapeutics (ALDX) and BIOFRONTERA AG/ADR (BFRA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Verastem (VSTM), Biocept (BIOC), Cronos Group (CRON), Evoke Pharma (EVOK), Ford Motor (F), Novavax (NVAX), Neovasc (NVCN) and AT&T (T).

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Pulmatrix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (2.31%) and Hussman Strategic Advisors Inc. (0.97%). View institutional ownership trends for Pulmatrix.

PULM stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Hussman Strategic Advisors Inc.. View insider buying and selling activity for Pulmatrix.

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PULM stock can currently be purchased for approximately $1.68.

Pulmatrix has a market capitalization of $42.71 million and generates $7.91 million in revenue each year. The biotechnology company earns $-20,600,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.

The official website for Pulmatrix is www.pulmatrix.com.

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]